Mutation and methylation analysis of TP53 in adrenal carcinogenesis

European Journal of Surgical Oncology

Volumn 31, Issue 5, 2005, Pages 549-554

  Sidhu, Stan ^a,b,h   Martin, E ^a,b   Gicquel, C ^c   Melki, J ^b,d   Clark, S J ^b,d   Campbell, P ^e,f   Magarey, C J ^f   Schulte, K M ^g   Roher H D ^g   Delbridge, L ^a,b   Robinson, B G ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e LIVERPOOL HOSPITAL   (Australia)

^f ST GEORGE HOSPITAL   (Australia)

^g HEINRICH HEINE UNIVERSITY   (Germany)

^h NONE   (Australia)

Author keywords

Adrenal gland neoplasms; DNA methylation; TP53

Indexed keywords

PROTEIN P53; SULFITE;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CARCINOGENESIS; CHROMOSOME 17P; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; EXON; FEMALE; FRAMESHIFT MUTATION; GENE AMPLIFICATION; GENE INACTIVATION; GENE MUTATION; GENETIC CODE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN METHYLATION; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

ADRENAL GLAND NEOPLASMS; ADULT; AGED; DNA METHYLATION; FEMALE; GENES, P53; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS (GENETICS); SEQUENCE ANALYSIS;

EID: 21144450186     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2005.01.013     Document Type: Article

References (22)

1. A.G. Knudson Jr Mutation and cancer: Statistical study of retinoblastoma Proc Natl Acad Sci USA 68 1971 820-823
2. A.J. Levine p53, the cellular gatekeeper for growth and division Cell 88 1997 323-331
3. T. Yano M. Linehan P. Anglard M.I. Lerman L.N. Daniel C.A. Stein et al. Genetic changes in human adrenocortical carcinomas J Natl Cancer Inst 81 1989 518-523
4. C. Gicquel X. Bertagna V. Gaston J. Coste A. Louvel E. Baudin et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors Cancer Res 61 2001 6762-6767
5. M. Kjellman O.P. Kallioniemi R. Karhu A. Hoog L.O.. Farnebo G. Auer et al. Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy Cancer Res 56 1996 4219-4223
6. S. Sidhu D.J. Marsh G. Theodosopoulos J. Philips C.P. Bambach P. Campbell et al. Comparative genomic hybridization analysis of adrenocortical tumors J Clin Endocrinol Metab 87 2002 3467-3474
7. H. Ohgaki P. Kleihues P.U. Heitz p53 mutations in sporadic adrenocortical tumors Int J Cancer 54 1993 408-410
8. M. Reincke M. Karl W.H. Travis G. Mastorakos B. Allolio H.M. Linehan et al. p53 mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies J Clin Endocrinol Metab 78 1994 790-794
9. R.C. Ribeiro F. Sandrini B. Figueiredo G.P. Zambetti E. Michalkiewicz A.R. Lafferty et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma Proc Natl Acad Sci USA 98 2001 9330-9335
10. A.C. Latronico E.M. Pinto S. Domenice M.C. Fragoso R.M. Martin M.C. Zerbini et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors J Clin Endocrinol Metab 86 2001 4970-4973
11. P. Hainaut Tumor-specific mutations in p53: The acid test Nat Med 8 2002 21-23
12. L. Barzon M. Chilosi F. Fallo G. Martignoni L. Montagna G. Palu et al. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors Eur J Endocrinol 145 2001 207-212
13. S.J. Clark J. Melki DNA methylation and gene silencing in cancer: Which is the guilty party? Oncogene 21 2002 5380-5387
14. J.R. Melki S.J. Clark DNA methylation changes in leukaemia Semin Cancer Biol 12 2002 347-357
15. K.D. Robertson DNA methylation, methyltransferases, and cancer Oncogene 20 2001 3139-3155
16. M. Schroeder M.J. Mass CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene Biochem Biophys Res Commun 235 1997 403-406
17. C.G. Mathew K.S. Chin D.F. Easton K. Thorpe C. Carter G.I. Liou et al. A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10 Nature 328 1987 527-528
18. L.M. Weiss L.J. Medeiros A.L. Vickery Jr Pathologic features of prognostic significance in adrenocortical carcinoma Am J Surg Pathol 13 1989 202-206
19. S.J. Clark J. Harrison C.L. Paul M. Frommer High sensitivity mapping of methylated cytosines Nucleic Acids Res 22 1994 2990-2997
20. P.A. Jones S.B. Baylin The fundamental role of epigenetic events in cancer Nat Rev Genet 3 2002 415-428
21. J.H. Kang S.J. Kim D.Y. Noh I.A. Park K.J. Choe O.J. Yoo et al. Methylation in the p53 promoter is a supplementary route to breast carcinogenesis: Correlation between CpG methylation in the p53 promoter and the mutation of the p53 gene in the progression from ductal carcinoma in situ to invasive ductal carcinoma Lab Invest 81 2001 573-579
22. I.P. Pogribny S.J. James Reduction of p53 gene expression in human primary hepatocellular carcinoma is associated with promoter region methylation without coding region mutation Cancer Lett 176 2002 169-174